Ring E-modified analogues of(-)-podophyllotoxin and etoposide and a method for their synthesis

ABSTRACT

A process of preparing ring E-modified analogues of (-)-podophyllotoxin as potential new chemotherapeutic agents. The process generates corresponding analogues of (-)-podophyllotoxin, itself, and allows new molecular interactions in the southern hemisphere (ring E) of the molecule. A method of preparing enantiomerically enriched compounds of the formula (I) and (II): ##STR1## wherein R is: ##STR2## wherein X, X&#39;, Y, Y&#39; and Z are ring E substituents and R 1  is one of a)-e) below. 
     a) --OH, 
     b) an ether or glycoside, 
     c) a substituted or unsubstituted amine or aniline, 
     d) a C 2  -C 8  alkenyl group, preferably --CH 2  CH═CH 2 , 
     e) a C 1  -C 8  alcohol, preferably --CH 2  CH 2  CH 2  OH. 
     The process produces enantiomerically enriched compounds which do not occur naturally and are not readily available from (-)-podophyllotoxin.

BACKGROUND OF THE INVENTION

Podophyllotoxin is a naturally occurring podophyllum lignan isolated from the roots of the apple mandrake tree. In 1946, podophyllotoxin was found to function as an antimitotic by inhibiting microtubule formation. Shortly thereafter, this lignan was examined as a potential antitumor agent, but was found to exhibit prohibitive toxicity in Phase I cancer trials. More recently, podophyllotoxin has been proposed as a medicinal agent for the treatment of psoriasis, malaria and rheumatoid arthritis (U.S. Pat. No. 4,788,216 (1988).

In the 1960's, medicinal chemists at Sandoz developed several promising semisynthetic derivatives of podophyllotoxin. Two of these, etoposide (VP-16), and teniposide (VM-26), showed promise as antitumor agents and so were developed further. Clinical trials began in 1967 for teniposide, and in 1971 for etoposide. The latter drug has been extensively employed as a chemotherapeutic ever since. Etoposide appears to act by promoting topoisomerase II-mediated DNA strand scission. The appearance of etoposide resistance, both through alterations in topo II and through MDR, underscores the importance of developing fundamentally new types of analogues. Its side effects appear to limited to myelosuppression, which may be controlled by carefully regulating dosage.

Etoposide has displayed remarkable efficacy as a single agent in the treatment of small cell lung cancer, testicular cancer, several leukemias and Kaposi's sarcoma (the tumor most closely associated with AIDS). More recently, etoposide has been identified as a very good candidate for the treatment of life-threatening cytomegalovirus (CMV) infections. The spectrum of carcinomas for which etoposide is effective has been expanded notably in recent years through the practice of combination therapy. Thus, encouraging clinical reports have appeared relating the application of etoposide to the treatment of cancers of the cervix, ovary, breast and prostate, as well as advanced Hodgkin's disease.

The clinical success of etoposide has also resulted in efforts to develop etoposide analogues, particularly in recent years. However, probably due to the lag in enantioselective total synthetic efforts in the area, etoposide analogues bearing modified aglycon moieties have been lacking. Instead, most efforts have focused upon semisynthesis, especially variation of the carbohydrate sector (thioetoposide and NK-61 1) or prodrug synthesis (e.g. etopophos (BMY-40481)). K. -H. Lee has been particularly prolific in this regard, having published a long series of papers describing largely "northern hemisphere" modifications of the natural product. This continues to be an active research area.

The chemistry leading from (-)-podophyllotoxin to etoposide has been well worked out. However, the path from (±)-podophyllotoxin to etoposide requires a tedious resolution step and is therefore not practical. Even so, most chemical syntheses of podophyllotoxin to date have led to racemic product.

SUMMARY OF THE INVENTION

With the synthetic route to the (-)-podophyllotoxin skeleton that constitutes the process of the present invention, previously unavailable ring E-modified analogues of etoposide can be constructed as potential new chemotherapeutic agents of this structural family. In addition, the process generates corresponding analogues of (-)-podophyllotoxin, itself. The process of the present invention allows new molecular interactions in the southern hemisphere (ring E) of the molecule.

The process of the present invention is directed to a method of preparing enantiomerically enriched compounds of the formulas (I) and (II): ##STR3## wherein R is: ##STR4## wherein X, X', Y, Y' and Z are ring E substituents and R¹ is one of a)-e) below.

a) --OH,

b) an ether or glycoside,

c) a substituted or unsubstituted amine or aniline,

d) a C₂ -C₈ alkenyl group, preferably --CH₂ CH═CH₂,

e) a C₁ -C₈ alcohol, preferably --CH₂ CH₂ CH₂ OH.

The present invention is also directed to enantiomerically enriched compounds which do not occur naturally and are not readily available from (-)-podophyllotoxin.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Prior to the present invention, all asymmetric approaches to the (-)-podophyllotoxin framework employed a chiral auxiliary. It was discovered that enantiomerically enriched 3',4',5'-tridemethoxy-(-)-podophyllotoxin could be synthesized, which is the ring-E fully deoxygenated analogue of (-)-podophyllotoxin. The process of the present invention differs from previous methods by installing the ring E late in the sequence, so as to permit convenient variation of this important sector of the molecule. Absolute stereochemistry is introduced catalytically, by means of an enzyme-mediated desymmetrization of an advanced meso intermediate.

The key steps in this process are: (i) elaboration of an enzymatically-derived, enantiomerically enriched, monoester into, a key Michael acceptor, (ii) systematic synthetic variation of ring E structure in the (-)-podophyllotoxin framework through conjugate addition to that Michael acceptor (iii) aglycon glycosylation (or appendage of other O-, N- and C-centered R¹ groups) to produce etoposide analogues.

In accordance with the present invention, enantiomerically enriched compounds corresponding to the formula (I) or (II) below are prepared. Enantiomerically enriched means that the enantiomeric ratio is at least 95:5, preferably at least 97:3, prior to recrystallization. ##STR5## wherein R is: ##STR6## X, X', Y, Y' and Z may each be X, X', Y, Y' and Z may be hydrogen; deuterium; tritium; a C₁ -C₈ saturated or unsaturated, alkyl or cycloalkyl group; a hydroxyl group; an ether-protected hydroxyl group bearing a C₁ -C₈ saturated or unsaturated alkyl or cyclic alkyl group; a carboxylate ester-protected hydroxyl group derived from a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, carboxylic acid; a hydroxyl group protected as a phosphate mono-, di- or triester, the di-, or triester having C₁ -C₄ saturated or unsaturated alkyl group(s); a phosphonate mono- or diester-protected hydroxyl group derived from a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, phosphonic acid wherein the diester also contains a C₁ -C₄ saturated or unsaturated alkyl group; a phosphinate ester-protected hydroxyl group derived from a phosphinic acid bearing two C₁ -C₈ saturated or unsaturated, cyclic or acyclic, alkyl groups; a hydroxyl group protected as a sulfate mono- or diester bearing a C₁ -C₄ saturated or unsaturated alkyl group; a hydroxyl group protected as a sulfonate ester derived from a sulfonic acid bearing a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, alkyl group; an ammo group; a primary or secondary amine bearing 1 to 2 C₁ -C₄ saturated or unsaturated alkyl group(s), respectively; a carboxamide-protected, unsubstituted or primary amino group bearing a C₁ -C₄ saturated or unsaturated alkyl group and derived from a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, carboxylic acid; a carboxylic acid; a carboxylate ester bearing a C₁ -C₄ saturated or unsaturated alkyl group; a phosphonic acid; a phosphonate mono- or diester bearing 1 to 2 C₁ -C₄ saturated or unsaturated alkyl group(s), respectively; a phosphinic acid having a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, alkyl group or ester bearing a C₁ -C₄ saturated or unsaturated alkyl group; a formyl group; an acetyl group; a benzoyl group; a carboxamide group derived from ammonia, or a primary or secondary amine bearing 1 to 2 C₁ -C₄ saturated or unsaturated alkyl group(s), respectively; a sulfhydryl group; a thioether bearing a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, alkyl group; a sulfonic acid, a sulfonate ester bearing a C₁ -C₄ saturated or unsaturated alkyl group; an alkylsulfonyl group bearing a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, alkyl group; a phenylsulfonyl group; a sulfoxide bearing a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, alkyl group; a phenylsulfoxide; a phenylseleno group; a phenylselenoxide; an azide; a halogen; a cyano group; a nitro group; a nitroso group; a diazonium group; or a trifluoromethyl group.

An unexpected result of the present invention is that many types of substitutents are available for ring E. This is obtained by the late addition of ring E during synthesis of the compounds.

R¹ is one of

a) --OH

b) an ether, such as --OCH₂ CH═CH₂, --OCH₂ Ph, and --OCH₂ CH₂ NH₂, or glycoside, preferably ##STR7## wherein R² is methyl or 2-thienyl, and R³ is --OH or N(CH₃)₂ ;

c) a substituted or unsubstituted amine or aniline including, but not limited to: ##STR8## where n=0-4, and R⁴, R⁵, R⁶, R⁷, and R⁸ are each independently selected from the group consisting of hydrogen; a saturated or unsaturated C₁ -C₈ alkyl or cycloalkyl, optionally substituted with a halogen or hydroxy; a halogen, or a hydroxy; a C₁ -C₈ alkoxy; a C₁ -C₈ alcohol; an ether having C₁ -C₈ alkyl groups; a carboxylate ester having C₁ -C₈ alkyl groups; an amide; a carboxylic acid; an amine, optionally substituted with one or more C₁ -C₄ alkyl group(s); NH₂.HCl, NH₂.HAc, NH₂ 1/2H₂ SO₄, NH₂.1/3H₃ PO₄, SO₂ H, SO₂ NH₂ ; a cyano group; a phosphate acid or ester having C₁ -C₈ alkyl groups; a phosphonic acid or ester having C₁ -C₈ alkyl groups; a nitro group; a nitroso group; an azide; a sulfone; a sulfoxide; a diazonium salt, phenyl, a substituted phenyl, phenoxy, substituted phenoxy, anilinyl, substituted anilinyl, cyclohexyl, piperidine, or a heterocyclic ring; or any two of R⁴ -R⁸ may together form a heterocyclic ring.

d) a C₂ -C₈ alkenyl group, preferably --CH₂ CH═CH₂ ;

e) a C₁ -C₈ alcohol, preferably --CH₂ CH₂ CH₂ OH.

Examples of suitable R¹ substituents include the substituents disclosed in U.S. Pat. Nos. 5,132,322; 5,300,500; 5,332,811; 5,541,223, which are each incorporated herein by reference, and which are included within the present invention.

In addition, the hydrogens at carbons 5 and 8 can be replaced with a halogen, such as Br, as disclosed by U.S. Pat. No. 5,132,322, which is incorporated by reference.

The method begins with a compound of formula (a) which can be obtained, for example, by the process described in Tetrahedron: Asymmetry 1996, 7(6), 1577-1580 (June 1996 issue) beginning from piperonal. The key meso diacetate is readily constructed in seven steps therefrom in which an isobenzofuran Diels-Alder reaction is the key step. PPL (porcine pancreatic lipase in crude form from Sigma Chemical Co.) selectively deacetylates the (R)-acetoxymethyl arm of the diacetate to form the compound of formula (a). Meso diacetate (compound (a)) is a substrate for a number of acyl transferases. PPL gives especially good results, in terms of both chemical and optical yield, furnishing (+)(a) (95% ee) in 66% yield (83% yield corrected for recovered diacetate).

The compound of formula (a) ##STR9## is converted by silylation, deacetylation, and oxidation to produce a compound of formula (b) without loss of optical activity. Silylation occurs with a silylating agent, R⁹ X, including but not limited to TIPSCl (triisopropylsilyl chloride), TBDMSCl (tert-butyldimethylsilyl chloride), and TBDPSCl (tert-butyldiphenylsilyl chloride), in the presence of an appropriate base such as imidazole or NEt₃. Deacetylation is carried out under standard conditions (e.g. K₂ CO₃, MeOH or Na, MeOH or NH₃, MeOH). The aldehyde is then oxidized to the corresponding aldehyde under mild two-electron oxidation conditions (e.g. Swern or Moffatt oxidation (DMSO as oxidant), Ley oxidation (TPAP=tetrapropylammonium perrhuthenate as oxidant) or Dess-Martin oxidation (Dess-Martin periodinane as oxidant.))

The compound of formula (b) ##STR10## wherein R⁹ is a silyl protecting group, is converted to a compound of formula (c) by retro-Michael ring opening and protection of the C₄ --OH followed by aldehyde oxidation. The ring opening occurs under typical Michael addition conditions (such as NaOMe and MeOH). The protection step must be carried out under basic conditions (to avoid aromatization) in the presence of an alkyl halide (e.g. allyl bromide, benzyl bromide) or halomethyl ether (e.g. BOMBr, SEMCl). Aldehyde oxidation proceeds smoothly under Lindgren conditions (NaClO₂ as oxidant) to give (c). The efficient retro-Michael ring-opening of (b) unveils the (methylenedioxy)cinnamyl system as the vehicle for late installation of ring E, the key step in this process.

The compound of formula (c) ##STR11## wherein R¹⁰ is a C₄ protecting group, such as SEM (2-trimethylsilyl)ethoxymethyl), BOM (benzyloxymethyl), benzyl, or allyl, is converted to a compound of formula (d) by transformation of the carboxylic acid into an acyl oxazolidinone functionality. This requires carboxyl activation (e.g. with carbonyl diimidazole) and then condensation with a metalated oxazolidinone to give (d). ##STR12##

As for relative stereochemistry, Michael acceptor (d) is designed to promote re face conjugate addition. In fact, Cu^(I) -mediated conjugate addition of RMgBr to (d) occurs exclusively from the desired re face and is quite efficient. Thus, the compound of formula (d) is converted to a compound of formula (e) by Cu^(I) -mediated conjugate addition of RMgBr at a temperature of -10 to 0° C. Because this introduction of ring E occurs late in this synthesis, the procedure provides for the convenient synthesis of a variety of ring E-congeners of (-)-podophyllotoxin. ##STR13##

The compound of formula (e) is converted to a compound of formula (f) by chemoselective silyl ether deprotection by heating with a fluoride source, such as TBAF, and cyclization to produce the corresponding lactone.; ##STR14##

The compound of formula (f) is converted to a compound of formula (I) by generation and kinetic quenching of a C₂ -enolate and deprotection of the C₄ --OH. If R¹⁰ =SEM, then it is particularly advantageous to use modified Kim conditions during this step. S. Kim et al. "Uses Butanethiol, MgBr₂ in Et₂ O to Deprotect SEM Ethers" Synlett (1991)183-184. Modified conditions substituted ethanethiol (EtSH) for butanethiol.

In any of the above steps, an appropriate solvent is used as is well within the skill of the art.

The present invention is also directed to an enantiomerically enriched compound corresponding to the formula (I) or (II): ##STR15## wherein R is: ##STR16## X, X', Y, Y' and Z may each be hydrogen; deuterium; tritium; a C₁ -C₈ saturated or unsaturated, alkyl or cycloalkyl group; a hydroxyl group; an ether-protected hydroxyl group bearing a C₁ -C₈ saturated or unsaturated alkyl or cyclic alkyl group; a carboxylate ester-protected hydroxyl group derived from a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, carboxylic acid; a hydroxyl group protected as a phosphate mono-, di- or triester, the di-, or triester having C₁ -C₄ saturated or unsaturated alkyl group(s); a phosphonate mono- or diester-protected hydroxyl group derived from a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, phosphonic acid wherein the diester also contains a C₁ -C₄ saturated or unsaturated alkyl group; a phosphinate ester-protected hydroxyl group derived from a phosphinic acid bearing two C₁ -C₈ saturated or unsaturated, cyclic or acyclic, alkyl groups; a hydroxyl group protected as a sulfate mono- or diester bearing a C₁ -C₄ saturated or unsaturated alkyl group; a hydroxyl group protected as a sulfonate ester derived from a sulfonic acid bearing a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, alkyl group; an amino group; a primary or secondary amine bearing 1 to 2 C₁ -C₄ saturated or unsaturated alkyl group(s), respectively; a carboxamide-protected, unsubstituted or primary amino group bearing a C₁ -C₄ saturated or unsaturated alkyl group and derived from a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, carboxylic acid; a carboxylic acid; a carboxylate ester bearing a C₁ -C₄ saturated or unsaturated alkyl group; a phosphonic acid; a phosphonate mono- or diester bearing 1 to 2 C₁ -C₄ saturated or unsaturated alkyl group(s), respectively; a phosphinic acid having a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, alkyl group or ester bearing a C₁ -C₄ saturated or unsaturated alkyl group; a formyl group; an acetyl group; a benzoyl group; a carboxamide group derived from ammonia, or a primary or secondary amine bearing 1 to 2 C₁ -C₄ saturated or unsaturated alkyl group(s), respectively; a sulfhydryl group; a thioether bearing a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, alkyl group; a sulfonic acid, a sulfonate ester bearing a C₁ -C₄ saturated or unsaturated alkyl group; an alkylsulfonyl group bearing a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, alkyl group; a phenylsulfonyl group; a sulfoxide bearing a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, alkyl group; a phenylsulfoxide; a phenylseleno group; a phenylselenoxide; an azide; a halogen; a cyano group; a nitro group; a nitroso group; a diazonium group; or a trifluoromethyl group;

with the proviso that only one of Y, Y', and Z can be a hydroxyl or an ether- or ester-protected hydroxyl group; and

R is one of

a) --OH;

b) ether or glycoside, preferably ##STR17## wherein R² is methyl or 2-thienyl, and R³ is --OH or N(CH₃)₂ ;

c) a substituted amine or aniline, as defined above;

d) a C₂ -C₈ alkenyl group, preferably --CH₂ CH═CH₂ ;

e) a C₁ -C₈ alcohol, preferably --CH₂ CH₂ CH₂ OH.

The present invention is also directed to an enantiomerically enriched compound corresponding to the formula (I) or (II): ##STR18## wherein R is: ##STR19## X, X', Y, Y' and Z may each be hydrogen; deuterium; tritium; a C₁ -C₈ saturated or unsaturated, alkyl or cycloalkyl group; a hydroxyl group; an ether-protected hydroxyl group bearing a C₁ -C₈ saturated or unsaturated alkyl or cyclic alkyl group; a carboxylate ester-protected hydroxyl group derived from a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, carboxylic acid; a hydroxyl group protected as a phosphate mono-, di- or triester, the di-, or triester having C₁ -C₄ saturated or unsaturated alkyl group(s); a phosphonate mono- or diester-protected hydroxyl group derived from a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, phosphonic acid wherein the diester also contains a C₁ -C₄ saturated or unsaturated alkyl group; a phosphinate ester-protected hydroxyl group derived from a phosphinic acid bearing two C₁ -C₈ saturated or unsaturated, cyclic or acyclic, alkyl groups; a hydroxyl group protected as a sulfate mono- or diester bearing a C₁ -C₄ saturated or unsaturated alkyl group; a hydroxyl group protected as a sulfonate ester derived from a sulfonic acid bearing a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, alkyl group; an amino group; a primary or secondary amine bearing 1 to 2 C₁ -C₄ saturated or unsaturated all group(s), respectively; a carboxamide-protected, unsubstituted or primary amino group bearing a C₁ -C₄ saturated or unsaturated alkyl group and derived from a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, carboxylic acid; a carboxylic acid; a carboxylate ester bearing a C₁ -C₄ saturated or unsaturated alkyl group; a phosphonic acid; a phosphonate mono- or diester bearing 1 to 2 C₁ -C₄ saturated or unsaturated alkyl group(s), respectively; a phosphinic acid having a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, alkyl group or ester bearing a C₁ -C₄ saturated or unsaturated alkyl group; a formyl group; an acetyl group; a benzoyl group; a carboxamide group derived from ammonia, or a primary or secondary amine bearing 1 to 2 C₁ -C₄ saturated or unsaturated alkyl group(s), respectively; a sulfhydryl group; a thioether bearing a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, alkyl group; a sulfonic acid, a sulfonate ester bearing a C₁ -C₄ saturated or unsaturated alkyl group; an alkylsulfonyl group bearing a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, alkyl group; a phenylsulfonyl group; a sulfoxide bearing a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, alkyl group; a phenylsulfoxide; a phenylseleno group; a phenylselenoxide; an azide; a halogen; a cyano group; a nitro group; a nitroso group; a diazonium group; or a trifluoromethyl group;

with the proviso that only two Y, Y' and Z can be a hydroxyl or an ether-or ester-protected hydroxyl group; and

R is one of

a) --OH;

b) ether or glycoside, preferably ##STR20## wherein R² is methyl or 2-thienyl, and R³ is --OH or N(CH₃)₂ ;

c) a substituted or unsubstituted amine or aniline as defined above;

d) a C₂ -C₈ alkenyl group, preferably --CH₂ CH═CH₂ ;

e) a C₁ -C₈ alcohol, preferably --CH₂ CH₂ CH₂ OH;

except the following compounds:

X and X'═H, Y═--OCH₃, Y'═H, --NH₂, --N⁺ .tbd.N, Cl, Br, I, Z═--OH;

X and X'═H, Y═OCH₃, Y'═OCH₃, Z═H, Cl or Br; and

X and X'═H, Y═OH, Y'═H, Z=OCH₃.

The above exception excludes known derivatives of (-)-podophyllotoxin and congeners in which either the 4'- or the 3'-methoxy groups are deoxygenated, as the literature (Saulmier, M. G. et al. 1989) teaches that these transformations are readily performed, albeit in several steps. Also excluded are the 3'-amino and 3'-diazonium derivatives (and obvious Sandmeyer coupling products thereform) en route to the 3 '-deoxy compound. Finally, the 4'-chloro and 4'-bromo derivatives are excluded as these may be obtained by subjecting (-)-podophyllotoxin to PCl₅ (Ayers et al. J. C. S. Perkin I, 1972, pp 1350-1355). The 3'-deoxy, 4-demethyl derivative of (-)-podophyllotoxin is excluded as it occurs naturally in plants (Wichers, H. J. et al. Phytochem. Vol. 30, 1991, pp3601-3604) and is known as NC 370.

The compounds prepared in accordance with the above method are suitable for use in pharmaceutical compositions along with a pharmaceutically acceptable carrier.

EXAMPLES

The invention will be further described by reference to the following examples. These examples should not be construed in any way as limiting the invention to anything less than that which is disclosed or which could have been obvious to anyone skilled in the art.

Example 1 ##STR21##

Compound (a) (14.5 g, 49.6 mmol) was dissolved in DMF (75 mL) and imidazole (7.4 g, 0.11 mol) was added. After stirring for 15 min, the reaction mixture was taken to ice bath. TIPSCl (11.7 mL, 54.6 mmol)/DMF (70 mL) was cannulated at 0° C., then the reaction mixture was stirred at room temperature under Ar for 9 h. The reaction mixture was diluted with Et₂ O (1 L) and washed with NaHCO₃ (3×150 mL) and HO (3×150 mL). The organic layer was dried over MgSO₄ and concentrated to give a silyl ether (b)(22.3 g, 100%). ##STR22##

¹ H NMR (360 MHz CDCl₃) δ1.03 (d, J=3 Hz, 18H), 1.03-1.22 (m, 3H), 2.06 (s, 3H), 2.76-2.77 (m, 3H), 3.14 (app t, J=10 Hz, 1H), 3.40-3.43 (m, 1H), 3.78 (dd, J=5, 11 Hz, 1H), 5.24(d, J=4 Hz, 1H), 5.33 (d, J=3 Hz, 1H), 5.94 (d, J=1 Hz, 1H), 5.97(d, J=1 Hz, 1H), 6.74 (s, 1H), 6.83 (s, 1H); ¹³ C NMR (75 MHz, CDCl₃) δ 12.5, 18.6, 21.5, 40.2, 44.3, 61.8, 63.3, 82.3, 82.9, 101.8, 103.6, 104.1, 136.9, 137.5, 147.1, 147.2, 171.3; [α]²¹ _(D) =+3.0° (c 0.9, CHCl₃). HRMS (FAB, 3-NOBA, LiI) calcd for C₂₄ H₃₆ O₆ SiLi 455.2442, obsd 455.2443.

To a solution of starting acetate (7.10 g, 15.8 mmol) in MeOH (60 mL) was added K₂ CO₃ (438 mg, 3.17 mmol). The resulting suspension was stirred for 4 hours at room temperature. Then, Et₂ O (100 mL) and Dowex 50×8 resin (H⁺ -form; 1.8 g) were added and stirring was continued for 1 h. Filtration and concentration yielded the desired alcohol (c) (6.43 g, 100%) as an oil: ##STR23##

¹ H NMR (300 MHz, CDCl₃) δ 0.98-1.07 (m, 21H), 2.79-2.85 (m, 2H), 2.97-3.11 (m, 2 H),3.17(dd, J=5,11 Hz, 1H),3.31(dd, J=6, 10 Hz, 1H),5.19(d, J=4 Hz, 1H),5.20 (d, J=5 Hz, 1H), 5.96 (s, 2H), 6.73 (s, 1H), 6.76 (s, 1H); ¹³ C NMR (75 MHz, CDCl₃) δ 12.4, 18.6, 44.4, 44.5, 61.1, 62.1, 82.0, 82.1, 101.9, 103.3, 103.4, 137.3, 137.6, 147.0, 147.1; IR (ATR) 3419 cm⁻¹ ; [α]²¹ _(D) =-26.8° (c 1.3, CHCl₃). HRMS (FAB, 3-NOBA, LiI) calcd for C₂₂ H₃₄ O₅ SiLi 413.2336, obsd 413.2341. ##STR24##

To a solution of oxalyl chloride (2.96 g 23.3 mmol) in CHCl₂ (11.6 mL) at -78° C. was added a solution of DMSO (2.06 g, 26.4 mmol) in CH₂ Cl₂ (9 mL) via cannula. After stirring for 10 min at -78° C., a solution of starting alcohol (6.30 g, 15.5 mmol) in CH₂ Cl₂ (9 mL) was added, dropwise via cannula. After an additional 30 min at -78° C., a solution of NEt₃ (4.72 g, 46.5 mmol) in CH₂ Cl₂ (6.5 mL) was added in the same manner. After 1 h at -78° C., additional CH₂ Cl₂ was added to facilitate stirring (continued for another 1 h). Et₂ O (100 mL) was then added at -78° C. and the reaction mixture was allowed to warm to rt. The crude reaction mixture was then poured into Et₂ O (300 mL) and extracted sequentially with H₂ O (3×150 mL), sat'd NH₄ Cl (aqueous, 2×150 mL) and sat'd NaCl (aqueous, 150 mL). After drying (MgSO₄), filtration and evaporation, aldehyde (d) (6.09 g, 97%) was obtained: ¹ H NMR (300 MHz, CDCl₃) δ 0.97-1.20 (m, 21H), 2.99-3.12 (m, 2H), 3.22 (ddd, J=3, 5, 8 Hz, 1H), 3.46-3.51 (m, 1H), 5.38 (s, 1H), 5.40 (s, 1H), 5.96 (d, J=1 Hz, 1H),5.98(d, J=1 Hz, 1H),6.84(s, 1H),6.85(s, 1H),9.07(d, J=3 Hz, 1H); ¹³ C NMR(125 MHz, CDCl₃) δ 12.6, 18.6, 47.3, 54.2, 62.8, 81.0, 82.7, 102.0, 103.9, 104.0, 136.9, 137.5, 147.4, 147.5, 202.5; [α]²¹ _(D) =-26.3° (c 0.8, CHCl₃). HRMS (FAB, 3-NOBA, NaI) calcd for C₂₂ H₃₂ O₅ SiNa 427.1917, obsd 427.1925. ##STR25##

To a solution of aldehyde (e) (10.5 g, 26.0 mmol) in absolute MeOH (95 mL) at rt was added freshly prepared NaOMe in MeOH (300 mL of a 60 mM solution). After 24 h at rt, the reaction was monitored by TLC and additional NaOMe (3×20 mL) was added at ca. 2 h intervals, until no (e) remained. H₂ O (245 mL) was then added and CO₂ was bubbled through the solution until the pH reached 8 (pH paper). MeOH was removed in vacuo, and the resulting aqueous layer was extracted with CH₂ Cl₂ (3×200 mL). The combined organics were dried (MgSO₄), filtered and evaporated to provide analytically pure product as a white solid (9.50 g, 90%): mp 87-89° C.; ¹ H NMR (500 MHz, CDCl₃) δ 0.93-1.03 (m, 21H), 1.74 (d, J=5 Hz, 1H), 3.17 (app t, J=10 Hz, 1H), 3.34 (ddd, J=2, 4, 6 Hz, 1H), 3.80 (dd, J=4, 10 Hz, 1H), 4.97 (app t, J=1 Hz, 1H), 6.01 (s, 1H), 6.02 (s, 1H), 6.83 (s, 1H), 6.93 (s, 1H), 7.24 (s, 1H), 9.61 (s, 1H); ¹³ C NMR (125 MHz, CDCl₃) δ 12.5, 18.5, 43.4, 62.7, 70.0, 102.4, 109.8, 110.9., 125.3, 133.8, 136.0, 145.6, 148.8, 150.7, 192.9; IR (ATR) 3395, 1674, 1645 cm⁻¹ ; [α]²¹ _(D) =+82.0° (c 1.0, CHCl₃); HRMS (FAB, 3-NOBA) calcd for C₂₂ H₃₃ O₅ Si [(M+H)⁺ ] 405.2097, obsd 405.2096. Anal. Calcd for C₂₂ H₃₂ O₅ Si: C, 65.31; H, 7.97. Found: C, 65.45; H, 7.98. ##STR26##

To a solution of starting alcohol (7.0 g, 17 mmol) in CH₂ C₂ (140 mL) at 0° C. were added sequentially, diisopropylethylamine (9.0 mL, 52 mmol) and SEM chloride (4.6 mL, 26 mmol). The resulting reaction mixture was allowed to warm slowly to room temperature overnight and then poured into sat'd NaHCO₃ (aqueous, 150 mL). The aqueous layer was further extracted with CH₂ Cl₂ (2×150 mL). After drying (MgSO₄), filtering and evaporating, the crude product was purified by SiO₂ chromatography (25 to 50% EtOAc-hexanes) to provide (f) (8.6 g, 93%): ¹ H NMR (360 MHz, CDCl₃) δ 0.00 (s, 9H), 0.91-1.04 (m, 23H), 3.07 (app t, J=10 Hz, 1H), 3.41 (ddd, J=2, 4, 6 Hz, 1H), 3.46-3.62 (m, 2H), 3.70 (dd, J=5, 10 Hz, 1H), 4.58 (d, J=7 Hz, 1H), 4.65 (d, J=7 Hz, 1H), 4.98 (d, J=1 Hz, 1H), 6.01 (d, J=2 Hz, 1H), 6.02 (d, J=1 Hz, 1H), 6.84 (s, 1H), 6.90 (s, 1H), 7.23 (s, 1H), 9.60 (s, 1H); 1³ C NMR (75 MHz, CDCl₃) 6-0.8, 12.5, 18.6, 18.7, 41.1, 61.8, 65.7, 72.3, 92.4, 102.4, 109.9, 112.1, 126.3, 130.7, 136.5, 145.7, 148.7, 150.2, 192.9; IR (ATR) 1674 cm⁻¹ ; [α]²¹ _(D) =+37.7° (c 0.9, CHCl₃). Anal. Calcd for C₂₈ H₄₆ O₆ Si₂ : C, 62.88; H, 8.67. Found: C, 63.00; H, 8.49. ##STR27##

To a solution of aldehyde (f) (3.5 g, 6.5 mmol) in t-BuOH (130 mL) and 2-methyl-2-butene (35 mL) at room temperature was added a solution of NaClO₂ (5.4 g, 60 mmol) and NaH₂ PO₄ (5.4 g) in H₂ O (60 mL). After being allowed to stir at room temperature overnight, the reaction mixture was extracted with Et₂ O (3×150 mL), dried and concentrated. Flash chromatography (0.5% MeOH-34.5% EtOAc-65% hexanes) provided the acid (g) (3.6 g, 100%). [On a larger scale, (f) (15.0 g, 28 mmol) gave the same acid in excellent yield (14.8 g, 95%)] ¹ H NMR (360 MHz, CDCl₃) δ 0.00 (s, 9H), 0.92-1.12 (m, 23H), 3.13 (app t, J=10 Hz, 1H), 3.38 (ddd, J=1, 5, 6 Hz, 1H), 3.47-3.65(m, 2H),3.78(dd, J=4, 10 Hz, 1H),4.61 (d, J=7 Hz, 1H),4.67(d, J=7 Hz, 1H), 4.97 (d, J=2 Hz, 1H), 5.99 (d, J=1 Hz, 1H), 6.01 (d, J=1 Hz, 1H), 6.80 (s, 1H), 6.88 (s, 1H), 7.63 (s, 1H); ¹³ C NMR (125 MHz, CDCl₃) 6-0.8, 12.6, 18.6, 18.7, 43.2, 62.0, 65.7, 72.6, 92.4, 102.2, 109.9, 112.0, 125.8, 126.5, 129.4, 139.1, 148.6, 149.6, 172.9; IR (ATR) 3854, 1676 cm⁻ ; [α]²¹ _(D) =+78.3° (c 1.6, CHCl₃). HRMS (FAB, 3-NOBA, NaI) calcd for C₂₈ H₄₆ O₇ Si₂ Na 573.2680, obsd 573.2677. ##STR28##

To a solution of starting acid (4.3 g, 7.8 mmol) in THF (20 mL) at room temperature was added carbonyl diimidazole (1.4 g, 8.6 mmol), whereupon gas evolution was immediately observed. After 3 h at room temperature, the reaction mixture was partitioned between Et₂ O (50 mL) and H₂ O (50 mL). The H₂ O-layer was further extracted once with Et₂ O (50 mL). The combined organics were dried and evaporated to provide the crude acyl imidazolide which was taken forward without further purification. The next transformation was generally carried out on a 100 mg-1 g scale, with the best yields being obtained on the smaller scales.

To a deoxygenated solution of 2-oxazolidinone (16 mg, 0.18 mmol) in THF (1 mL) at -78° C. was added n-BuLi (130 mL of a 1.4 M solution in hexanes, 0.18 mmol). The resulting reaction mixture was allowed to stir for 1 h at -78° C. Then a solution of acyl imidazolide (100 mg, 0.166 mmol) in THF (1 mL) was added, dropwise, via cannula at -78 ° C. After 4.5 h at -78° C., the reaction mixture was diluted with Et₂ O (5 mL) and then extracted with KO (3×4 mL). The organic layer was dried (MgSO₄), filtered, concentrated and chromatographed (NEt₃ -EtOAc-hexanes: 2:49:49) to yield (h) (62 mg, 60%). [On a larger scale, acyl imidazolide (1.8 g, 3.0 mmol) provided (h) (840 mg, 45%).] mp 110-112° C.; ¹ H NMR (500 MHz, CDCl₃) 6-0.01 (s, 9H), 0.93-1.03 (m, 23H), 3.22 (app t, J=10 Hz, 1H), 3.44 (ddd, J=2, 6, 7 Hz, 1H), 3.52 (app dt, J=6, 10 Hz, 1H), 3.61 (app dt, J=6, 11 Hz, 1H), 3.71 (app dd, J=6, 10 Hz, 1H), 3.95 (ddd, J=6, 8, 10 Hz, 1H), 4.09-4.15 (m, 1H), 4.37-4.44 (m, 2H), 4.60 (d, J=7 Hz, 1H), 4.68 (d, J=7 Hz, 1H), 4.94 (d, J=2 Hz, 1H), 5.96 (d, J=2 Hz, 1H), 5.98 (d, J=1 Hz, 1H), 6.74 (s, 1H), 6.86 (s, 1H), 7.12 (s, 1H); ¹³ C NMR (125 MHz, CDCl₃) δ -0.78, 12.5, 18.6, 18.7, 43.7, 44.7, 62.4, 62.8, 65.6, 71.7, 92.3, 102.2, 109.9, 112.0, 126.2, 127.1, 128.7, 138.0, 148.6, 149.4, 154.2, 170.2; IR (ATR) 1781, 1663 cm⁻¹ ; [α]²¹ _(D) =+69.9° (c 3.0, CHCl₃). Anal. Calcd for C₃₁ H₄₉ NO₈ Si₂ : C, 60.06; H, 7.97; N, 2.26. Found: C, 60.19; H. 7.70; N, 2.32. ##STR29##

To a suspension of CuCN (1.62 g, 18.1 mmol) in THF (17 mL) and Me₂ S (17 mL) at -78° C., was added PhMgBr (21.5 mL of a 1.0 M solution in Et₂ O). The resulting mixture was allowed to stir 1.5 h at -78° C., whereupon a solution of (h) (1.40 g, 2.26 mmol) in THF (12.5 mL) was added via cannula. After 3 h at -40° C., sat'd NH₄ Cl (aqueous, 40 mL) was added, followed by Et₂ O (75 mL). After further extraction of the aqueous layer with Et₂ O (2×50 mL), the combined organics were dried (M_(g) SO₄), filtered and evaporated. Chromatography (25% EtOAc-hexanes) yielded (i) (1.23 g, 78%): ¹ H NMR (360 MHz, CDCl₃) δ 0.04 (s, 9H), 0.96-1.06 (m, 23H), 2.70-2.75 (m, 1H), 3.49 (dd, J=9, 10 Hz, 1H), 3.60-3.67 (m, 1H), 3.75 (dd, J=5, 11 Hz, 1H), 3.81-3.91 (m, 3 H), 4.19-4.31 (m, 2H), 4.44 (d, J=11 Hz, 1H), 4.80-4.86 (m, 2H), 4.87 (d, J=3 Hz, 1 H),4.93(d, J=7 Hz, 1H), 5.81(d, J=1 Hz, 1H),5.86(d, J=1 Hz, 1H),6.22(s, 1H), 6.73 (s, 1H), 7.21-7.23 (m, 5H); ¹³ C NMR (125 MHz, CDCl₃) δ -0.7, 12.6, 18.6, 18.8, 42.4, 43.4, 44.0, 45.6, 61.5, 62.4, 65.7, 73.0, 93.1, 101.5, 110.0, 110.6, 127.1, 127.8, 129.0, 130.2, 133.6, 145.7, 146.7, 148.3, 153.2, 174.4; IR (ATR) 1784, 1695 cm⁻¹ ; [α]²¹ _(D) =-106.9° (c 3.6, CHCl₃). Anal. Calcd for C₃₇ H₅₅ NO₈ Si₂ : C, 63.67; H. 7.94; N, 2.01. Found: C, 63.72; H, 7.78; N, 1.86. ##STR30##

To a solution of (i) (647 mg, 928 mmol) in THF (5 mL) at room temperature was added TBAF (1.85 mL of a 1.0 M solution in THF). The resulting reaction mixture was heated at 40-50° C. for 5 h. After cooling to room temperature, the volatiles were evaporated in vacuo. The residue was taken up in dry PhH--CHCl₃ (1:1; 20 mL) and concentrated on a rotary evaporator to remove H₂ O. This procedure was repeated twice. Then the crude product was partitioned between CH₂ Cl₂ (40 mL) and sat'd NH₄ Cl (aqueous, 40 mL). After further extraction of the aqueous layer with CH₂ Cl₂ (2×40 mL), the crude product was subjected to SiO₂ chromatography (25% EtOAc-hexanes) to provide (i)(336 mg, 80%) as a white solid: mp 121-123° C.; ¹ H NMR (500 MHz, CDCl₃) δ 0.02 (s, 9H), 0.90-1.00 (m, 2H), 2.92-2.98 (m, 1H), 3.26 (dd, J=5, 10 Hz, 1H), 3.53-3.59 (m, 1H), 3.70-3.75 (m, 1H), 4.23 (d, J=5 Hz, 1H), 4.29 (dd, J=4, 10 Hz, 1H), 4.41 (dd, J=7, 9 Hz, 1H),4.50(d, J=7 Hz, 1H),4.71(s, 1H),5.90(d, J=1 Hz, 1H),5.91(d, J=1 Hz, 1H), 6.39 (s, 1H), 6.88 (s, 1H), 6.39-7.33 (m, 5H); ¹³ C NMR (125 MHz, CDCl₃) δ -0.8, 18.8, 41.5, 45.1, 45.7, 66.6, 70.6, 75.7, 94.7, 101.8, 107.8, 110.3, 127.5, 129.1, 129.2, 129.8, 132.1, 143.9, 147.4, 148.3, 178.7; IR (ATR) 1765, 1753 cm⁻¹ ; [α]²¹ _(D) =+106.5° (c 1.1, CHCl₃). Anal. Calcd for C₂₅ H₃₀ O₆ Si: C, 66.05; H, 6.65. Found: C, 65.83; H, 6.49. ##STR31##

To a solution of diisopropyl amine (430 ML, 3.1 mmol) in THF (7 mL) at -78° C., was added n-BuLi (1.95 mL of a 1.4 M solution in hexanes, 2.7 mmol). After stirring for 30 min at 0° C., the resulting LDA solution was cooled to -78° C., whereupon a solution of (j) (700 mg, 1.54 mmol) in THF (8.5 mL) was added dropwise via cannula at -78° C. After stirring this solution for 90 min at -78° C., a suspension of freshly prepared pyridinium hydrochloride (890 mg, 7.7 mmol) in THF (3×2 mL) was added. The transfer was effected in three portions due to the limited solubility of the salt in THF. After allowing the reaction mixture to come to room temperature, it was poured into sat'd NH₄ Cl (aqueous, 30 mL) and CHCl₃ (50 mL). Following a second extraction with CHCl₃ (50 mL), the organics were dried (MgSO₄), filtered, concentrated and flushed through an SiO₂ column (35% EtOAc-hexanes) to give a mixture of diastereomeric lactones (j) (656 mg, 94%; trans:cis=2:1 by ¹ H NMR). This diastereomeric mixture (650 mg, 1.43 mmol) was taken up in Et₂ O (₁₁ mL) and PhH (2.7 mL). MgBr₂ --Et₂ O complex (554 mg 2.15 mmol) was added under Ar atmosphere in a glove bag. To the resulting solution at 0° C. was added EtSH (265 mL, 3.58 mmol) dropwise, via syringe. After 2 h at 0° C. and 6 h at room temperature, additional MgBr₂ --Et₂ O (170 mg, 0.66 mmol) and EtSH (100 mL; 1.35 mmol) were added, as before. After 3 h (0° C. to room temp), the reaction was quenched by the addition of sat'd NaHCO₃ (15 mL) and extracted thrice with CH₂ Cl₂ (15 mL portions). The combined organics were dried (MgSO₄), filtered, and concentrated. Flash chromatography (25 to 50% EtOAc-hexanes) gave (k) (170 mg, 32%) in a first fraction, and (l) (220 mg, 47%) in a second fraction:

For (k): mp 180-182° C.; ¹ H NMR (500 MHz, CDCl₃) δ 1.95 (d, J=9 Hz, 1H), 2.71-2.80 (im, 1H), 2.86 (dd, J=5, 14 Hz, 1H), 4.08 (dd, J=9, 10 Hz, 1H), 4.57 (dd, J=7, 9 Hz, 1H), 4.63 (d, J=5 Hz, 1H), 4.77 (app t, J=9 Hz, 1H), 5.95 (s, 2H), 6.45 (s, 1H), 7.13-7.26 (m, 6H); ¹³ C NMR (125 MHz, CD₂ Cl₂ /CD₃ OD) δ 40.9, 44.6, 45.5, 72.4 (2C), 101.9, 106.9, 109.8, 127.4, 128.2, 131.3, 131.9, 134.6, 141.0, 148.0, 148.1, 176.0; IR (ATR) 3411, 1754 cm⁻¹ ; [α]²¹ _(D) =-154° (c 0.16, EtOH) Anal. Calcd for C₁₉ H₁₆ O₅ : C, 70.36; H, 4.97. Found: C, 70.56; H, 5.16.

For l: ¹ H NMR (500 MHz, CDCl₃) δ 1.28 (app dt, J=1, 7 Hz, 3H), 2.58 (q, J=7, 15 Hz, 2H),2.86-2.88(m, 1H), 3.13 (dd, J=4, 8 Hz, 1H), 3.68 (d, J=8 Hz, 1H), 4.31 (d, J=4 Hz, 1H),4.36(dd, J=6, 10 Hz, 1H), 4.44(dd, J=2,9 Hz, 1H), 5.90(s, 1H), 5.91 (s, 1H), 6.35 (s, 1H), 7.17-7.34 (m, 6H); ¹³ C NMR (75 MHz, CDCl₃) δ 15.1, 25.6, 40.5, 44.1, 46.3, 47.4, 72.4, 101.8, 108.9, 110.2, 127.6, 129.2, 129.4, 129.6, 131.4, 144.8, 147.6, 147.7, 177.7; IR (AIR) 1770 cm⁻¹ ; [α]²¹ _(D) =-55.4° (c 0.2, CHCl₃). HRMS (FAB, 3-NOBA, NaI) calcd for C₂₁ H₂₀ O₄ SNa 391.0980, obsd 391.0977.

Example 2 ##STR32##

To a suspension of CuCN (0.58 g, 6.45 mmol) in THF (15 mL) and Me₂ S (15 mL) at -10° C., was added p-CH₃ C₆ H₅ MgBr (6.45 mL of a 1.0 M solution in Et₂ O). The resulting mixture was allowed to stir 1 h at -10° C., whereupon a solution of h (example 1) (0.5 g, 0.81 mmol) in THF (15 mL) was added via cannula. After 20 min at -10° C., sat'd NH₄ Cl (aqueous, 15 mL) was added, followed by Et₂ O (25 mL). After further extraction of the aqueous layer with Et₂ O (2×20 mL), the combined organics were dried (MgSO₄), filtered and evaporated. Chromatography (10% EtOAc-hexanes) yielded product (0.486 g, 84.7%).

Example 3 ##STR33##

To a suspension of CuCN (0.87 g, 9.68 mmol) in THF (45 mL) at -10° C., was added p-ClC₆ H₅ MgBr (9.68 mL of a 1.0 M solution in THF). The resulting mixture was allowed to stir 1 h at -10° C., whereupon a solution of h (example 1) (0.75 g, 1.21 mmol) in THF (22.5 mL) was added via cannula. After 12 min at -10° C., sat'd NH₄ Cl (aqueous, 20 mL) was added, followed by Et₂ O (40 mL). After further extraction of the aqueous layer with Et₂ O (2×25 mL), the combined organics were dried (MgSO₄), filtered and evaporated. Chromatography (10% EtOAc-hexanes) yielded product (0.66 g, 75%).

Example 4 ##STR34##

To a suspension of CuCN (0.87 g, 9.68 mmol) in THF (45 mL) at -10° C., was added p-FC₆ H₅ MgBr (9.68 mL of a 1.0 M solution in THF). The resulting mixture was allowed to stir 1 h at -10° C., whereupon a solution of h(example 1) (0.75 g, 1.21 mmol) in THF (22.5 mL) was added via cannula. After 2 h at -10° C., sat'd NH₄ Cl (aqueous, 20 mL) was added, followed by Et₂ O (40 mL). After further extraction of the aqueous layer with Et₂ O (2×25 mL), the combined organics were dried (MgSO₄), filtered and evaporated. Chromatography (10% EtOAc-hexanes) yielded product (0.51 g, 59.0%).

Example 5 ##STR35##

To a suspension of CuCN (1.445 g, 16.13 mmol) in THF (75 ML) at -10° C., was added p-tert-BuC₆ H₅ MgBr (8.07 mL of a 2.0 M solution in THF). The resulting mixture was allowed to stir 1 h at -10° C., whereupon a solution of h (example 1) (1.25 g, 2.02 mmol) in THF (37.5 mL) was added via cannula. After 20 min at -10° C., sat'd NH₄ Cl (aqueous, 35 mL) was added, followed by Et₂ O (70 mL). After further extraction of the aqueous layer with Et₂ O (2×45 mL), the combined organics were dried (MgSO₄), filtered and evaporated. Chromatography (10% EtOAc-hexanes) yielded product (1.14 g, 75%).

It will be apparent to those skilled in the art that various modifications and variations can be made in the compositions and methods of the present invention without departing from the spirit or scope of the invention. Thus, it is intended that the present invention cover the modifications and variations of this invention provided they come within the scope of the appended claims and their equivalents. 

What is claimed is:
 1. A process for preparing an enantiomerically enriched compound corresponding to the formula (I) or (II): ##STR36## wherein R is: ##STR37## and X, X', Y, Y' and Z may each be hydrogen; deuterium; tritium; a C₁ -C₈ saturated or unsaturated, alkyl or cycloalkyl group; a hydroxyl group; an ether-protected hydroxyl group bearing a C₁ -C₈ saturated or unsaturated alkyl or cyclic alkyl group; a carboxylate ester-protected hydroxyl group derived from a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, carboxylic acid; a hydroxyl group protected as a phosphate mono-, di- or triester, the di-, or triester having C₁ -C₄ saturated or unsaturated alkyl group(s); a phosphonate mono- or diester-protected hydroxyl group derived from a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, phosphonic acid wherein the diester also contains a C₁ -C₄ saturated or unsaturated alkyl group; a phosphinate ester-protected hydroxyl group derived from a phosphinic acid bearing two C₁ -C₈ saturated or unsaturated, cyclic or acyclic, alkyl groups; a hydroxyl group protected as a sulfate mono- or diester bearing a C₁ -C₄ saturated or unsaturated alkyl group; a hydroxyl group protected as a sulfonate ester derived from a sulfonic acid bearing a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, alkyl group; an amino group; a primary or secondary amine bearing 1 to 2 C₁ -C₄ saturated or unsaturated alkyl group(s), respectively; a carboxamide-protected, unsubstituted or primary amino group bearing a C₁ -C₄ saturated or unsaturated alkyl group and derived from a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, carboxylic acid; a carboxylic acid; a carboxylate ester bearing a C₁ -C₄ saturated or unsaturated alkyl group; a phosphonic acid; a phosphonate mono- or diester bearing 1 to 2 C₁ -C₄ saturated or unsaturated alkyl group(s), respectively; a phosphinic acid having a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, alkyl group or ester bearing a C₁ -C₄ saturated or unsaturated alkyl group; a formyl group; an acetyl group; a benzoyl group; a carboxamide group derived from ammonia, or a primary or secondary amine bearing 1 to 2 C₁ -C₄ saturated or unsaturated alkyl group(s), respectively; a sulfhydryl group; a thioether bearing a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, alkyl group; a sulfonic acid, a sulfonate ester bearing a C₁ -C₄ saturated or unsaturated alkyl group; an alkylsulfonyl group bearing a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, alkyl group; a phenylsulfonyl group; a sulfoxide bearing a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, alkyl group; a phenylsulfoxide; a phenylseleno group; a phenylselenoxide; an azide; a halogen; a cyano group; a nitro group; a nitroso group; a diazonium group; or a trifluoromethyl group; and R¹ is one ofa) --OH; b) an ether or glycoside; c) a substituted or unsubstituted amine or aniline; d) a C₂ to C₈ alkenyl group; e) a C₁ to C₈ alcohol;comprising subjecting a compound of formula (a); ##STR38## to silylation, deacetylation, and oxidation to produce a compound of formula (b) ##STR39## wherein R⁹ is a silyl protecting group; converting the compound of formula (b) to a compound of formula (c) by retro-Michael ring opening and protection of the C₄ --OH followed by aldehyde oxidation ##STR40## wherein R¹⁰ is a C₄ protecting group; converting the compound of formula (c) to a compound of formula (d) by transformation of the carboxylic acid into an acyl oxazolidinone functionality; ##STR41## converting the compound of formula (d) to a compound of formula (e) by Cu^(I) -mediated conjugate addition of RMgBr at a temperature of -10 to 0° C.; ##STR42## converting the compound of formula (e) to a compound of formula (f) by chemoselective silyl ether deprotection by heating with a fluoride source and cyclization to produce the corresponding lactone; ##STR43## converting the compound of formula (f) to a compound of formula (I) by generation and kinetic quenching of a C₂ enolate and deprotection of the C₄ OH.
 2. The process according to claim 1 wherein R¹ is ##STR44## wherein R is methyl or thienyl, and R³ is --OH or N(CH₃)₂.
 3. The process according to claim 1 wherein R¹ is ##STR45## wherein n=0-4 and R⁴, R⁵, R⁶, R⁷, and R⁸ are each independently selected from the group consisting of hydrogen; a saturated or unsaturated C₁ -C₈ alkyl or cycloalkyl, optionally substituted with a halogen or hydroxy; a halogen, or a hydroxy; a C₁ -C₈ alkoxy; a C₁ -C₈ alcohol; an ether having C₁ -C₈ alkyl groups; a carboxylate ester having C₁ -C₈ alkyl groups; an amide; a carboxylic acid; an amine, optionally substituted with one or more C₁ -C₄ allyl group(s); NH₂.HCl, NH₂.HAc, NH₂ 1/2H₂ SO₄, NH₂.1/3H₃ PO₄, SO₂ K SO₂ NH₂ ; a cyano group; a phosphate acid or ester having C₁ -C₈ alkyl groups; a phosphonic acid or ester having C₁ -C₈ alkyl groups; a nitro group; a nitroso group; an azide; a sulfone; a sulfoxide; a diazonium salt, phenyl, a substituted phenyl, phenoxy, substituted phenoxy, anilinyl, substituted anilinyl, cyclohexyl, piperidine, or a heterocyclic ring; or any two of R⁴ -R⁸ may together form a heterocyclic ring.
 4. The process according to claim 1 wherein the silylating agent is TIPSCl.
 5. The process according to claim 1 wherein the oxidation is Swern oxidation.
 6. The process according to claim 1 wherein R¹⁰ is SEM.
 7. The process according to claim 6 wherein the compound of formula (f) is converted to the compound of formula (I) under modified Kim conditions.
 8. A process of converting a compound of formula (d) ##STR46## to a compound of formula (e) comprising Cu^(I) -mediated conjugate addition of RMgBr at a temperature of -10 to 0° C. ##STR47## wherein R is ##STR48## and X X', Y, Y' and Z may each be hydrogen; deuterium; tritium; a C₁ -C₈ saturated or unsaturated, alkyl or cycloalkyl group; a hydroxyl group; an ether-protected hydroxyl group bearing a C₁ -C₈ saturated or unsaturated alkyl or cyclic alkyl group; a carboxylate ester-protected hydroxyl group derived from a C₁ -C, saturated or unsaturated, cyclic or acyclic, carboxylic acid; a hydroxyl group protected as a phosphate mono-, di- or triester, the di-, or triester having C₁ -C₄ saturated or unsaturated alkyl group(s); a phosphonate mono- or diester-protected hydroxyl group derived from a C₁ -C, saturated or unsaturated, cyclic or acyclic, phosphonic acid wherein the diester also contains a C₁ -C₄ saturated or unsaturated alkyl group; a phosphinate ester-protected hydroxyl group derived from a phosphinic acid bearing two C₁ -C₈ saturated or unsaturated, cyclic or acyclic, alkyl groups; a hydroxyl group protected as a sulfate mono- or diester bearing a C₁ -C₄ saturated or unsaturated alkyl group; a hydroxyl group protected as a sulfonate ester derived from a sulfonic acid bearing a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, alkyl group; an amino group; a primary or secondary amine bearing 1 to 2 C₁ -C₄ saturated or unsaturated alkyl group(s), respectively; a carboxamide-protected, unsubstituted or primary amino group bearing a C₁ -C₄ saturated or unsaturated alkyl group and derived from a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, carboxylic acid; a carboxylic acid; a carboxylate ester bearing a C₁ -C₄ saturated or unsaturated alkyl group; a phosphonic acid; a phosphonate mono- or diester bearing 1 to 2 C₁ -C₄ saturated or unsaturated alkyl group(s), respectively; a phosphinic acid having a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, alkyl group or ester bearing a C₁ -C₄ saturated or unsaturated alkyl group; a formyl group; an acetyl group; a benzoyl group; a carboxamide group derived from ammonia, or a primary or secondary amine bearing 1 to 2 C₁ -C₄ saturated or unsaturated alkyl group(s), respectively; a sulfhydryl group; a thioether bearing a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, alkyl group; a sulfonic acid, a sulfonate ester bearing a C₁ -C₄ saturated or unsaturated alkyl group; an alkylsulfonyl group bearing a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, alkyl group; a phenylsulfonyl group; a sulfoxide bearing a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, alkyl group; a phenylsulfoxide; a phenylseleno group; a phenylselenoxide; an azide; a halogen; a cyano group; a nitro group; a nitroso group; a diazonium group; or a trifluoromethyl group; R⁹ is a silyl protecting group; and R¹⁰ is a C₄ protecting group.
 9. The process according to claim 1 wherein R¹⁰ is SEM and R⁹ is TIPS.
 10. An enantiomerically enriched compound corresponding to the formula (I) or (II): ##STR49## wherein R is: ##STR50## and X X', Y, Y' and Z may each be hydrogen; deuterium; tritium; a C₁ -C₈ saturated or unsaturated, alkyl or cycloalkyl group; a hydroxyl group; an ether-protected hydroxyl group bearing a C₁ -C₈ saturated or unsaturated alkyl or cyclic alkyl group; a carboxylate ester-protected hydroxyl group derived from a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, carboxylic acid; a hydroxyl group protected as a phosphate mono-, di- or triester, the di-, or triester having C₁ -C₄ saturated or unsaturated alkyl group(s); a phosphonate mono- or diester-protected hydroxyl group derived from a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, phosphonic acid wherein the diester also contains a C₁ -C₄ saturated or unsaturated alkyl group; a phosphinate ester-protected hydroxyl group derived from a phosphinic acid bearing two C₁ -C₈ saturated or unsaturated, cyclic or acyclic, alkyl groups; a hydroxyl group protected as a sulfate mono- or diester bearing a C₁ -C₄ saturated or unsaturated alkyl group; a hydroxyl group protected as a sulfonate ester derived from a sulfonic acid bearing a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, alkyl group; an amino group; a primary or secondary amine bearing 1 to 2 C₁ -C₄ saturated or unsaturated alkyl group(s), respectively; a carboxamide-protected, unsubstituted or primary amino group bearing a C₁ -C₄ saturated or unsaturated alkyl group and derived from a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, carboxylic acid; a carboxylic acid; a carboxylate ester bearing a C₁ -C₄ saturated or unsaturated alkyl group; a phosphonic acid; a phosphonate mono- or diester bearing 1 to 2 C₁ -C₄ saturated or unsaturated alkyl group(s), respectively; a phosphinic acid having a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, alkyl group or ester bearing a C₁ -C₄ saturated or unsaturated alkyl group; a formyl group; an acetyl group; a benzoyl group; a carboxamide group derived from ammonia, or a primary or secondary amine bearing 1 to 2 C₁ -C₄ saturated or unsaturated alkyl group(s), respectively; a sulfhydryl group; a thioether bearing a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, alkyl group; a sulfonic acid, a sulfonate ester bearing a C₁ -C₄ saturated or unsaturated alkyl group; an alkylsulfonyl group bearing a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, alkyl group; a phenylsulfonyl group; a sulfoxide bearing a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, alkyl group; a phenylsulfoxide; a phenylseleno group; a phenylselenoxide; an azide; a halogen; a cyano group; a nitro group; a nitroso group; a diazonium group; or a trifluoromethyl group; andwith the proviso that only two of Y, Y', and Z can be a hydroxyl or an ether- or ester-protected hydroxyl group; with the further proviso that when X, X', Y, Y' are H, Z cannot be hydrogen, hydroxyl, an alkoxy, or a protected hydroxyl group and when X, X' are H, and Z is hydroxyl, an alkoxy or a protected hydroxyl group, neither Y or Y' can be an alkoxy;R¹ is one of a) --OH; b) an ether or a glycoside; c) a substituted or unsubstituted amine or aniline; d) a C₂ to C₈ alkenyl group; e) a C₁ to C₈ alcohol;except the following compounds: X and X'═H, Y═--OCH₃, Y'═H, --NH₂, --N⁺ .tbd.N, Cl, Br, I, Z═--OH; X and X'═H, Y═OCH₃, Y'═OCH₃, Z═H, Cl or Br; X and X'═H, Y═OH, Y'═H, Z═OCH₃ prepared by subjecting a compound of formula (a); ##STR51## to silylation, deacetylation, and oxidation to produce a compound of formula (b) ##STR52## wherein R⁹ is a silyl protecting group; converting the compound of formula (b) to a compound of formula (c) by retro-Michael ring opening and protection of the C₄ --OH followed by aldehyde oxidation ##STR53## wherein R¹⁰ is a C₄ protecting group; converting the compound of formula (c) to a compound of formula (d) by transformation of the carboxylic acid into an acyl oxazolidinone functionality; ##STR54## converting the compound of formula (d) to a compound of formula (e) by Cu^(I) -mediated conjugate addition of RMgBr at a temperature of -10 to 0° C.; ##STR55## converting the compound of formula (e) to a compound of formula (f) by chemoselective silyl ether deprotection by heating with a fluoride source and cyclization to produce the corresponding lactone; ##STR56## converting the compound of formula (f) to a compound of formula (I) by generation and kinetic quenching of a C₂ enolate and deprotection of the C₄ OH.
 11. The process according to claim 10 wherein R¹ is ##STR57## wherein R² is methyl or thienyl, and R³ is --OH or N(CH₃)₂.
 12. The process according to claim 10 wherein R¹ is ##STR58## wherein n=0-4 and R⁴, R⁵, R⁶, R⁷, and R⁸ are each independently selected from the group consisting of hydrogen; a saturated or unsaturated C₁ -C₈ alkyl or cycloalkyl, optionally substituted with a halogen or hydroxy; a halogen, or a hydroxy; a C₁ -C₈ alkoxy; a C₁ -C₈ alcohol; an ether having C₁ -C₈ alkyl groups; a carboxylate ester having C₁ -C₈ alkyl groups; an amide; a carboxylic acid; an amine, optionally substituted with one or more C₁ -C₄ alkyl group(s); NH₂.HCl, NH₂.HAc, NH₂ 1/2H₂ SO₄, NH₂.1/3H₃ PO₄, SO₂ H, SO₂ NH₂ ; a cyano group; a phosphate acid or ester having C₁ -C₈ alkyl groups; a phosphonic acid or ester having C₁ -C₈ alkyl groups; a nitro group; a nitroso group; an azide; a sulfone; a sulfoxide; a diazonium salt, phenyl, a substituted phenyl, phenoxy, substituted phenoxy, anilinyl, substituted anilinyl, cyclohexyl, piperidine, or a heterocyclic ring; or any two of R⁴ -R⁸ may together form a heterocyclic ring.
 13. The process according to claim 10 wherein the silylating agent is TIPSCl.
 14. The process according to claim 10 wherein the oxidation is Swern oxidation.
 15. The process according to claim 10 wherein R¹⁰ is SEM.
 16. The process according to claim 15 wherein the compound of formula (f) is converted to the compound of formula (I) under modified Kim conditions.
 17. An enantiomerically enriched compound corresponding to the formula (I) or (II): ##STR59## wherein R is: ##STR60## and X, X', Y, Y' and Z may each he hydrogen; deuterium; tritium; a C₁ -C₈ saturated or unsaturated, alkyl or cycloalkyl group; a hydroxyl group; an ether-protected hydroxyl group hearing a C₁ -C₈ saturated or unsaturated alkyl or cyclic alkyl group; a carboxylate ester-protected hydroxyl group derived from a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, carboxylic acid; a hydroxyl group protected as a phosphate mono-, di- or triester, the di-, or triester having C₁ -C₄ saturated or unsaturated alkyl group(s); a phosphonate mono- or diester-protected hydroxyl group derived from a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, phosphonic acid wherein the diester also contains a C₁ -C₄ saturated or unsaturated alkyl group; a phosphinate ester-protected hydroxyl group derived from a phosphinic acid bearing two C₁ -C₈ saturated or unsaturated, cyclic or acyclic, alkyl groups; a hydroxyl group protected as a sulfate mono- or diester bearing a C₁ -C₄ saturated or unsaturated alkyl group; a hydroxyl group protected as a sulfonate ester derived from a sulfonic acid bearing a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, alkyl group; an amino group; a primary or secondary amine bearing 1 to 2 C₁ -C₄ saturated or unsaturated alkyl group(s), respectively; a carboxamide-protected, unsubstituted or primary bearing a C₁ -C₄ saturated or unsaturated alkyl group; amino group derived from a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, carboxylic acid; a carboxylic acid; a carboxylate ester bearing a C₁ -C₄ saturated or unsaturated alkyl group; a phosphonic acid; a phosphonate mono- or diester bearing 1 to 2 C₁₋ C₄ saturated or unsaturated alkyl group(s), respectively; a phosphinic acid having a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, alkyl group or ester bearing a C₁ -C₄ saturated or unsaturated alkyl group; a formyl group; an acetyl group; a benzoyl group; a carboxamide group derived from ammonia, or a primary or secondary amine bearing 1 to 2 C₁ -C₄ saturated or unsaturated alkyl group(s), respectively; a sulfhydryl group; a thioether bearing a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, alkyl group; a sulfonic acid, a sulfonate ester bearing a C₁ -C₄ saturated or unsaturated alkyl group; an alkylsulfonyl group bearing a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, alkyl group; a phenylsulfonyl group; a sulfoxide bearing a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, alkyl group; a phenylsulfoxide; a phenylseleno group; a phenylselenoxide; an azide; a halogen; a cyano group; a nitro group; a nitroso group; a diazonium group; or a trifluoromethyl group;with the proviso that only one of Y, Y', and Z can be a hydroxyl or an ether- or ester-protected hydroxyl group; with the further proviso that when X, X', Y, Y' are H, Z cannot be hydrogen, hydroxyl, an alkoxy, or a protected hydroxyl group; andR is one of a) --OH; b) an ether or a glycoside; c) a substituted amine or aniline; d) a C₂ to C₈ alkenyl; e) a C₁ to C₈ alcohol.
 18. The compound of claim 17 wherein R¹ is ##STR61## wherein R² is methyl or thienyl, and R³ is --OH or N(CH₃)₂.
 19. The compound of claim 17 wherein R¹ is ##STR62## wherein n=0-4 and R⁴, R⁵, R⁶, R⁷, and R⁸ are each independently selected from the group consisting of hydrogen; a saturated or unsaturated C₁ -C₈ alkyl or cycloalkyl, optionally substituted with a halogen or hydroxy; a halogen, or a hydroxy; a C₁ -C₈ alkoxy; a C₁ -C₈ alcohol; an ether having C₁ -C₈ alkyl groups; a carboxylate ester having C₁ -C₈ alkyl groups; an amide; a carboxylic acid; an amine, optionally substituted with one or more C₁ -C₄ alkyl group(s); NH₂.HCl, NH₂.HAc, NH₂ 1/2H₂ SO₄, NH₂.1/3H₃ PO₄, SO₂ H, SO₂ NH₂ ; a cyano group; a phosphate acid or ester having C₁ -C₈ alkyl groups; a phosphonic acid or ester having C₁ -C₈ alkyl groups; a nitro group; a nitroso group; an azide; a sulfone; a sulfoxide; a diazonium salt, phenyl, a substituted phenyl, phenoxy, substituted phenoxy, anilinyl, substituted anilinyl, cyclohexyl, piperidine, or a heterocyclic ring; or any two of R⁴ -R⁸ may together form a heterocyclic ring.
 20. An enantiomerically enriched compound corresponding to the formula (I) or (II): ##STR63## wherein R is: ##STR64## and X, X', Y, Y' and Z may each be hydrogen; deuterium; tritium; a C₁ -C₈ saturated or unsaturated, alkyl or cycloalkyl group; a hydroxyl group; an ether-protected hydroxyl group bearing a C₁ -C₈ saturated or unsaturated alkyl or cyclic alkyl group; a carboxylate ester-protected hydroxyl group derived from a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, carboxylic acid; a hydroxyl group protected as a phosphate mono-, di- or triester, the di-, or triester having C₁ -C₄ saturated or unsaturated alkyl group(s); a phosphonate mono- or diester-protected hydroxyl group derived from a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, phosphonic acid wherein the diester also contains a C₁ -C₄ saturated or unsaturated alkyl group; a phosphinate ester-protected hydroxyl group derived from a phosphinic acid bearing two C₁ -C₈ saturated or unsaturated, cyclic or acyclic, alkyl groups; a hydroxyl group protected as a sulfate mono- or diester bearing a C₁ -C₄ saturated or unsaturated alkyl group; a hydroxyl group protected as a sulfonate ester derived from a sulfonic acid bearing a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, alkyl group; an amino group; a primary or secondary amine bearing 1 to 2 C₁ -C₄ saturated or unsaturated alkyl group(s), respectively; a carboxamide-protected, unsubstituted or primary bearing a C₁ -C₄ saturated or unsaturated alkyl group; amino group derived from a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, carboxylic acid; a carboxylic acid; a carboxylate ester bearing a C₁ -C₄ saturated or unsaturated alkyl group; a phosphonic acid; a phosphonate mono- or diester bearing 1 to 2 C₁ -C₄ saturated or unsaturated alkyl group(s), respectively; a phosphinic acid having a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, alkyl group or ester bearing a C₁ -C₄ saturated or unsaturated alkyl group; a formyl group; an acetyl group; a benzoyl group; a carboxamide group derived from ammonia, or a primary or secondary amine bearing 1 to 2 C₁ -C₄ saturated or unsaturated alkyl group(s), respectively; a sulfhydryl group; a thioether bearing a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, alkyl group; a sulfonic acid, a sulfonate ester bearing a C₁ -C₄ saturated or unsaturated alkyl group; an alkylsulfonyl group bearing a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, alkyl group; a phenylsulfonyl group; a sulfoxide bearing a C₁ -C₈ saturated or unsaturated, cyclic or acyclic, alkyl group; a phenylsulfoxide; a phenylseleno group; a phenylselenoxide; an azide; a halogen; a cyano group; a nitro group; a nitroso group; a diazonium group; or a trifluoromethyl group;with the proviso that only two of Y, Y', and Z can be a hydroxyl or an ether- or ester-protected hydroxyl group; with the further proviso that when X, X', Y, Y' are H, Z cannot be hydrogen, hydroxyl, an alkoxy, or a protected hydroxyl group and when X, X' are H, and Z is hydroxyl, an alkoxy or a protected hydroxyl group, neither Y or Y' can be an alkoxy; andR is one of a) --OH; b) an ether or a glycoside; c) A substituted or unsubstituted amine or aniline; d) a C₂ to C₈ alkenyl; e) a C₁ to C₈ alcohol;except the following compounds: X and X'═H, Y═--OCH₃, Y'═H, --NH₂, --N⁺ .tbd.N, Cl, Br, I, Z═--OH; X and X'═H, Y═OCH₃, Y'═OCH₃, Z═H, Cl or Br; X and X'═H, Y═OH, Y'═H, Z═OCH₃.
 21. The compound of claim 20 wherein R¹ is ##STR65## wherein R² is methyl or thienyl, and R³ is --OH or N(CH₃)₂.
 22. The compound of claim 20 wherein R¹ is ##STR66## wherein n=0-4 and R⁴, R⁵, R⁶, R⁷, and R⁸ are each independently selected from the group consisting of hydrogen; a saturated or unsaturated C₁ -C.sub. alkyl or cycloalkyl, optionally substituted with a halogen or hydroxy; a halogen, or a hydroxy; a C₁ -C₈ alkoxy; a C₁ -C₈ alcohol; an ether having C₁ -C₈ alkyl groups; a carboxylate ester having C₁ -C₈ alkyl groups; an amide; a carboxylic acid; an amine, optionally substituted with one or more C₁ -C₄ alkyl group(s); NH₂.HCl, NH₂.HAc, NH₂ 1/2H₂ SO₄, NH₂.1/3H₃ PO₄, SO₂ H, SO₂ NH₂ ; a cyano group; a phosphate acid or ester having C₁ -C₈ alkyl groups; a phosphonic acid or ester having C₁ -C₈ alkyl groups; a nitro group; a nitroso group; an azide; a sulfone; a sulfoxide; a diazonium salt, phenyl, a substituted phenyl, phenoxy, substituted phenoxy, anilinyl, substituted anilinyl, cyclohexyl, piperidine, or a heterocyclic ring; or any two of R⁴ -R⁸ may together form a heterocyclic ring.
 23. The process according to claim 1 wherein R¹ is --CH₂ CH═CH₂ or --CH₂ CH₂ CH₂ OH.
 24. The compound according to claim 10 wherein R¹ is --CH₂ CH═CH₂ or --CH₂ CH₂ CH₂ OH.
 25. The compound according to claim 17 wherein R¹ is --CH₂ CH═CH₂ or --CH₂ CH₂ CH₂ OH.
 26. The compound according to claim 20 wherein R¹ is --CH₂ CH═CH₂ or --CH₂ CH₂ CH₂ OH.
 27. A pharmaceutical composition comprising the compound of claims 10, 17, or 20 and a pharmaceutically acceptable carrier. 